Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis

• Published in: Human vaccines & immunotherapeutics 2015, Vol.11 (3), p.657-661
• Main Authors: Tirado, Yanely, Puig, Alina, Alvarez, Nadine, Borrero, Reinier, Aguilar, Alicia, Camacho, Frank, Reyes, Fatima, Fernández, Sonsire, Pérez, José Luis, Espinoza, Dulce Mata, Payán, Jorge Alberto Barrios, Sarmiento, María Elena, Norazmi, Mohd-Nor, Hernández-Pando, Rogelio, Acosta, Armando
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - administration & dosage; Alum Compounds - administration & dosage; Animals; Bacterial Load; BCG; BCG, Bacillus Calmette-Guerin; CFU, Colony Forming Unit; Disease Models, Animal; Lung - microbiology; Male; Mice, Inbred BALB C; Mtb, Mycobacterium tuberculosis; Mycobacterium bovis - chemistry; Mycobacterium bovis - immunology; Mycobacterium tuberculosis - isolation & purification; PBS, Phosphate Buffer Solution; PL Proteoliposomes; PLBCG, Proteoliposomes obtained from BCG; PLBCG-Al, PLBCG adjuvanted with alum; prime-boost; Proteolipids - administration & dosage; Proteolipids - immunology; Proteolipids - isolation & purification; proteoliposomes; SD, standard deviation; Short Report; TB, Tuberculosis; Tuberculosis; Tuberculosis - immunology; Tuberculosis - prevention & control; Tuberculosis Vaccines - administration & dosage; Tuberculosis Vaccines - immunology; Tuberculosis Vaccines - isolation & purification; vaccines
• ISSN: 2164-5515; 2164-554X
• DOI: 10.1080/21645515.2015.1011566

Tuberculosis (TB) is one of the most important causes of mortality and morbidity due to infectious diseases. BCG, the vaccine in use, is not fully protective against TB. In a previous study, we have shown that proteoliposomes (outer membrane extracts), obtained from BCG (PLBCG) were able to induce humoral immune responses against Mycobacterium tuberculosis (Mtb) antigens. With the objective to evaluate the protective capability of PLBCG alone or as a booster with BCG, a murine model of progressive pulmonary TB was used. Animals immunized with PLBCG adjuvanted with alum (PLBCG-Al) showed similar protection to that conferred by BCG. The group immunized with PLBCG-Al as a booster to BCG gave superior protection than BCG as evidenced by a reduction of bacterial load in lungs 2 months after infection with Mtb. Animals immunized with BCG, PLBCG-Al and this formulation as a booster of BCG, showed a significant decrease of tissue damage (percentage of pneumonic area/lung) compared with non-immunized animals. These results demonstrate that immunization with PLBCG-Al alone or as a booster to BCG induce appropriate protection against challenge with Mtb in mice and support the future evaluation of PLBCG as a promising vaccine candidate against Mtb.